ARDX Ardelyx Inc

Price (delayed)

$0.5625

Market cap

$81.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$72.8M

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate ...

Highlights
Ardelyx's debt has decreased by 27% YoY and by 15% QoQ
The company's gross margin rose by 9% QoQ and by 7% YoY
The net income has decreased by 46% YoY but it has increased by 3.2% from the previous quarter
The EPS has declined by 22% year-on-year but it has increased by 9% since the previous quarter
The company's revenue has shrunk by 69% YoY and by 61% QoQ
The company's gross profit has shrunk by 67% YoY and by 57% QoQ

Key stats

What are the main financial stats of ARDX
Market
Shares outstanding
144.6M
Market cap
$81.34M
Enterprise value
$72.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.14
Price to sales (P/S)
18.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.28
Earnings
Revenue
$3.98M
EBIT
-$148.93M
EBITDA
-$144.36M
Free cash flow
-$136.25M
Per share
EPS
-$1.39
Free cash flow per share
-$1.04
Book value per share
$0.49
Revenue per share
$0.03
TBVPS
$0.99
Balance sheet
Total assets
$129.41M
Total liabilities
$65.22M
Debt
$38.54M
Equity
$64.19M
Working capital
$66.38M
Liquidity
Debt to equity
0.6
Current ratio
2.39
Quick ratio
1.97
Net debt/EBITDA
0.06
Margins
EBITDA margin
-3,624.3%
Gross margin
97.9%
Net margin
-3,843.4%
Operating margin
-3,769.7%
Efficiency
Return on assets
-93.5%
Return on equity
-177.1%
Return on invested capital
-164.6%
Return on capital employed
-182.6%
Return on sales
-3,739.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARDX stock price

How has the Ardelyx stock price performed over time
Intraday
-1.75%
1 week
-8.39%
1 month
-14.44%
1 year
-92.82%
YTD
-48.86%
QTD
-47.43%

Financial performance

How have Ardelyx's revenue and profit performed over time
Revenue
$3.98M
Gross profit
$3.9M
Operating income
-$150.15M
Net income
-$153.08M
Gross margin
97.9%
Net margin
-3,843.4%
ARDX's operating margin has dropped by 147% since the previous quarter
Ardelyx's net margin has shrunk by 145% QoQ
The company's revenue has shrunk by 69% YoY and by 61% QoQ
The company's gross profit has shrunk by 67% YoY and by 57% QoQ

Growth

What is Ardelyx's growth rate over time

Valuation

What is Ardelyx stock price valuation
P/E
N/A
P/B
1.14
P/S
18.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.28
The EPS has declined by 22% year-on-year but it has increased by 9% since the previous quarter
ARDX's P/B is 60% below its last 4 quarters average of 2.9 and 59% below its 5-year quarterly average of 2.8
Ardelyx's equity has shrunk by 51% YoY and by 22% QoQ
The price to sales (P/S) is 82% lower than the 5-year quarterly average of 107.1 and 37% lower than the last 4 quarters average of 30.1
The company's revenue has shrunk by 69% YoY and by 61% QoQ

Efficiency

How efficient is Ardelyx business performance
The return on sales has dropped by 146% since the previous quarter
The company's return on invested capital has shrunk by 127% YoY and by 14% QoQ
Ardelyx's ROE has plunged by 125% YoY and by 15% from the previous quarter
Ardelyx's ROA has plunged by 84% YoY and by 9% from the previous quarter

Dividends

What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARDX.

Financial health

How did Ardelyx financials performed over time
ARDX's total assets is 98% greater than its total liabilities
The company's quick ratio has shrunk by 55% YoY and by 11% QoQ
The company's current ratio has shrunk by 51% YoY and by 6% QoQ
Ardelyx's debt is 40% lower than its equity
Ardelyx's equity has shrunk by 51% YoY and by 22% QoQ
Ardelyx's debt to equity has surged by 50% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.